Synthesis, crystal structural, and spectral characterisation of dabigatran etexilate tetrahydrate

被引：4

作者：

Cai, Zhi-Qiang ^{[1
]}

Hou, Xu ^{[1
]}

Kong, Du-Lin ^{[2
]}

Hou, Ling ^{[1
]}

Hu, Zhi-Quan ^{[1
]}

机构：

[1] Shenyang Univ Technol, Sch Petrochem Engn, Liaoyang 111003, Liaoning, Peoples R China

[2] Hainan Med Univ, Sch Pharmaceut Sci, Haikou 571199, Hainan, Peoples R China

来源：

JOURNAL OF CHEMICAL RESEARCH | 2016年 / 08期

关键词：

dabigatran etexilate; thrombin inhibitor; tetrahydrate; crystal structure; thermal analysis; DIRECT THROMBIN INHIBITOR; ATRIAL-FIBRILLATION; VENOUS THROMBOEMBOLISM; STROKE PREVENTION; ANTICOAGULATION; WARFARIN; PHARMACODYNAMICS; PHARMACOKINETICS; HEMORRHAGE; HEPARIN;

D O I：

10.3184/174751916X14664340623037

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Dabigatran etexilate tetrahydrate, C34H49N7O9, has been crystallised at ambient conditions. The colourless crystal was investigated using X-ray crystallography with single crystals and powder techniques, and was characterised by thermogravimetric-differential thermal analysis (TG-DTA) and infrared spectroscopy (IR). The compound was shown to be a tetrahydrate. A dabigatran etexilate molecule and four water molecules form a large ring structure, and intra-molecular hydrogen bonds contribute to the formation of a stable molecule in the unit cell.

引用

页码：461 / 466

页数：6

共 29 条

[1]

[Anonymous], 2018, UPD INF RISK BLOOD C

[2] Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation [J].

Barco, Stefano ;

Coppens, Michiel ;

van den Dool, Erik-Jan ;

van de Kerkhof, Daan ;

Stroobants, An K. ;

Middeldorp, Saskia .

THROMBOSIS AND HAEMOSTASIS, 2014, 112 (04) :836-838

[3]

Beliavskaia O O, 2014, Angiol Sosud Khir, V20, P37

[4] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].

Blech, Stefan ;

Ebner, Thomas ;

Ludwig-Schwellinger, Eva ;

Stangier, Joachim ;

Roth, Willy .

DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399

[5]

Brian D J, 1996, SYNTHETIC COMMUN, V26, P4351

[6] Study-Randomized Evaluation of Dabigatran Etexilate Compared to Warfarin in Pulmonary Vein Ablation: Assessment of an Uninterrupted Periprocedural Anticoagulation Strategy [J].

Calkins, Hugh ;

Gerstenfeld, Edward P. ;

Schilling, Richard ;

Verma, Atul ;

Willems, Stephan .

AMERICAN JOURNAL OF CARDIOLOGY, 2015, 115 (01) :154-155

[7] THROMBIN ACTIVE-SITE INHIBITORS [J].

DAS, J ;

KIMBALL, SD .

BIOORGANIC & MEDICINAL CHEMISTRY, 1995, 3 (08) :999-1007

[8] Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden [J].

Davidson, Thomas ;

Husberg, Magnus ;

Janzon, Magnus ;

Oldgren, Jonas ;

Levin, Lars-Ake .

EUROPEAN HEART JOURNAL, 2013, 34 (03) :177-183

[9] New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities [J].

Dobesh, Paul P. ;

Fanikos, John .

DRUGS, 2014, 74 (17) :2015-2032

[10] Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation [J].

Eikelboom, J. W. ;

Quinlan, D. J. ;

Connolly, S. J. ;

Hart, R. G. ;

Yusuf, S. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (05) :966-968

← 1 2 3 →